Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines that target specific neurocircuits in the brain through receptor-associated proteins (RAPs). The company addresses a fundamental challenge in neuromedicine by creating small molecule therapeutics that can selectively modulate disease-driving neural circuits, overcoming the indiscriminate effects of conventional neurological treatments that often result in limited efficacy and significant side effects. Rapport's pipeline targets central nervous system disorders including focal epilepsy, pain, bipolar disorder, and hearing disorders. The company's lead program, RAP-219, represents a novel approach to neuroanatomical specificity by selectively targeting TARPγ8, a receptor protein associated with clinically validated epilepsy targets. Founded in 2022 through a collaboration between Third Rock Ventures and Johnson & Johnson Innovation, Rapport operates from offices in Boston, Massachusetts and San Diego, California, positioning itself at the forefront of precision neuromedicine innovation.